Medicine
NovoLog Mix 70/30 100 IU/mL injectable suspension
NovoLog Mix 70/30 100 IU/mL injectable suspension is a prescription medicine containing Insulin aspart for subcutaneous use, marketed by Novo Nordisk Pharmaceutical Industries, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians. It ships in a temperature-controlled cold chain.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Cold chain
Store unused NOVOLOG MIX 70/30 in a refrigerator between 2°C to 8°C (36°F to…
Key facts
- Active ingredient (INN)
- Insulin aspart
- Brand
- NovoLog Mix 70/30
- Strength
- 100 IU/mL
- Dosage form
- Injectable suspension
- Route
- Subcutaneous
- Packs
- 1 vial, 5 syringes and 3 more
- Marketing authorisation holder
- Novo Nordisk Pharmaceutical Industries
- Manufacturers
- Novo Nordisk Pharmaceutical IndustriesA-S Medication SolutionsRemedyrepack
- Origin register
- US FDA, United States
- Storage
- Store unused NOVOLOG MIX 70/30 in a refrigerator between 2°C to 8°C (36°F to 46°F). Do not freeze NOVOLOG MIX 70/30 or use NOVOLOG MIX 70/30 if it has been frozen. The storage conditions are summarized in the following table: Table 7: Storage conditions for NOVOLOG MIX 70/30 vial and FlexPen Not in-use (unopened) Room Temperature (up to 30°C [86°F]) Not in-use (unopened) Refrigerated (2°C to 8°C…
- Cold chain
- Yes, shipped temperature controlled
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- A10AB05 Insulin aspart
- HS code (indicative)
- 3004.31Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 1 November 2001
- Identifiers
- RxCUI 351297, 847191, 977840 +1DailyMed set ID 1861fcee-7673-4afe-a206-08fa05c0add2, 66da64f7-ca50-47d2-95fa-de37005eef85, 19888a44-b330-462a-864d-338c5893dd63NDC 0169-2201, 70518-2119, 0169-3685 +3Application BLA021172
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial, glass in 1 carton / 10 mL in 1 vial, glass | 0169-2200-11 | Novo Nordisk Pharmaceutical Industries | 1 July 2021 |
| 5 syringe in 1 carton / 3 mL in 1 syringe | 0169-2201-25 | Novo Nordisk Pharmaceutical Industries | 1 July 2021 |
| 1 vial, glass in 1 carton / 10 mL in 1 vial, glass | 0169-3685-12 | Novo Nordisk Pharmaceutical Industries | 1 November 2001 |
| 5 syringe in 1 carton / 3 mL in 1 syringe | 0169-3696-19 | Novo Nordisk Pharmaceutical Industries | 11 September 2002 |
| 5 syringe, plastic in 1 carton / 3 mL in 1 syringe, plastic | 50090-2272-0 | A-S Medication Solutions | 15 December 2015 |
| 5 syringe, plastic in 1 carton / 3 mL in 1 syringe, plastic | 70518-2119-0 | Remedyrepack | 28 May 2019 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Alternatives
Other makers and brands of Insulin aspart 100 IU/mL injectable suspension.
Other strengths and forms of Insulin aspart
Clinical summary
Insulin aspart is an insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. It is available as injection and injectable suspension for subcutaneous and intravenous use. MedsAcross supplies Insulin aspart for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Insulin aspartFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Fiasp prescribing information (Novo Nordisk) · U.S. National Library of Medicine, DailyMed
- Fiasp: European public assessment report (EPAR) · European Medicines Agency
- NovoMix: European public assessment report (EPAR) · European Medicines Agency
Need NovoLog Mix 70/30 100 IU/mL injectable suspension for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.